Nicolas Noiseux

Dr. Nicolas Noiseux


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2010 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
BNBa-Khoi Nguyen
Ba-Khoi Nguyen
SMSimon Maltais
Simon Maltais
LPLouis P. Perrault
Louis P. Perrault
JTJean-François Tanguay
Jean-François Tanguay
JTJean-Claude Tardif
Jean-Claude Tardif
NNNicolas Noiseux
Nicolas Noiseux

5 October 2021 in Circulation
Verified
Journal Article
Open access
PDF file
Matthias ThielmannMatthias Thielmann
Matthias Thielmann
DCDavid Corteville
David Corteville
GSGabor Szabó
Gabor Szabó
MSMadhav Swaminathan
Madhav Swaminathan
ALAndre Lamy
Andre Lamy
CMC. David Mazer
C. David Mazer
Background: Acute kidney injury (AKI) affects up to 30% of patients undergoing cardiac surgery, leading to increased in-hospital and long-term morbidity and mortality. Teprasiran is a novel small interfering RNA that temporarily inhibits p53-mediated cell death that underlies AKI. Methods: This prospective, multicenter, double-blind, randomized, controlled phase 2 trial evaluated the efficacy and safety of a single 10 mg/kg dose of teprasiran versus placebo (1:1), in reducing the incidence, severity, and duration of AKI after cardiac surgery in high-risk patients. The primary end point was the proportion of patients who developed AKI determined by serum creatinine by postoperative day 5. Other end points included AKI severity and duration using various prespecified criteria. To inform future clinical development, a composite end point of major adverse kidney events at day 90, including death, renal replacement therapy, and ≥25% reduction of estimated glomerular filtration rate was assessed. Both serum creatinine and serum cystatin-C were used for estimated glomerular filtration rate assessments. Results: A total of 360 patients were randomly assigned in 41 centers; 341 dosed patients were 73±7.5 years of age (mean±SD), 72% were men, and median European System for Cardiac Operative Risk Evaluation score was 2.6%. Demographics and surgical parameters were similar between groups. AKI incidence was 37% for teprasiran- versus 50% for placebo-treated patients, a 12.8% absolute risk reduction, P =0.02; odds ratio, 0.58 (95% CI, 0.37–0.92). AKI severity and duration were also improved with teprasiran: 2.5% of teprasiran- versus 6.7% of placebo-treated patients had grade 3 AKI; 7% teprasiran- versus 13% placebo-treated patients had AKI lasting for 5 days. No significant difference was observed for the major adverse kidney events at day 90 composite in the overall population. No safety issues were identified with teprasiran treatment. Conclusions: The incidence, severity, and duration of early AKI in high-risk patients undergoing cardiac surgery were significantly reduced after teprasiran administration. A phase 3 study with a major adverse kidney event at day 90 primary outcome that has recently completed enrollment was designed on the basis of these findings (NCT03510897). Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02610283.

1 November 2012 in Endocrinology
Verified
Journal Article
Open access
PDF file
NNNicolas Noiseux
Nicolas Noiseux
MBMélanie Borie
Mélanie Borie
ADAlexandra Desnoyers
Alexandra Desnoyers
AMAhmed Menaouar
Ahmed Menaouar
LSLouis Mathieu Stevens
Louis Mathieu Stevens
JGJolanta Gutkowska
Jolanta Gutkowska
Principal limitation of cell therapy is cell loss after transplantation because of the interplay between ischemia, inflammation, and apoptosis. We investigated the mechanism of preconditioning of mesenchymal stem cells (MSCs) with oxytocin (OT), which has been proposed as a novel strategy for enhancing therapeutic potential of these cells in ischemic heart. In this study, we demonstrate that rat MSCs express binding sites for OT receptor and OT receptor transcript and protein as detected by RT-PCR and immunofluorescence, respectively. In response to OT (10−10 to 10−6m) treatment, MSCs respond with rapid calcium mobilization and up-regulation of the protective protein kinase B (PKB or Akt) and phospho-ERK1/2 proteins. In OT-stimulated cells, phospho-Akt accumulates intracellularly close to the mitochondrial marker cytochrome c oxidase subunit 4. Functional analyses reveal the involvement of Akt/ERK1/2 pathways in cell proliferation, migration, and protection against the cytotoxic and apoptotic effects of hypoxia and serum deprivation. In addition, OT preconditioning increases MSC glucose uptake. Genes with angiogenic, antiapoptotic, and cardiac antiremodeling properties, such as heat shock proteins (hsps) HSP27, HSP32, HSP70, vascular endothelial growth factor, thrombospondin, tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2, TIMP-3, and matrix metalloproteinase-2, were also up-regulated upon OT exposure. Moreover, coculture with OT-preconditioned MSC reduces apoptosis, as measured using terminal transferase dUTP nick end labeling assay in newborn rat cardiomyocytes exposed to hypoxia and reoxygenation. In conclusion, these results indicate that OT treatment evokes MSC protection through both intrinsic pathways and secretion of cytoprotective factors. Ex vivo cellular treatment with OT represents an attractive strategy aimed to maximize the biological and functional properties of effector cells.

9 July 2014 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
SSS Der Sarkissian
S Der Sarkissian
JCJ‐F Cailhier
J‐F Cailhier
MBM Borie
M Borie
LSL‐M Stevens
L‐M Stevens
LGL Gaboury
L Gaboury
NNNicolas Noiseux
Nicolas Noiseux
Background and Purpose: Celastrol, a triterpene from plants, has been used in traditional oriental medicine to treat various diseases. Here, we investigated the cardioprotective effects of celastrol against ischaemia.Experimental Approach: Protective pathways induced by celastrol were investigated in hypoxic cultures of H9c2 rat cardiomyoblasts and in a rat model of myocardial infarction, assessed with echocardiographic and histological analysis.Key Results: In H9c2 cells, celastrol triggered reactive oxygen species (ROS) formation within minutes, induced nuclear translocation of the transcription factor heat shock factor 1 (HSF1) resulting in a heat shock response (HSR) leading to increased expression of heat shock proteins (HSPs). ROS scavenger N‐acetylcysteine reduced expression of HSP70 and HSP32 (haeme oxygenase‐1, HO‐1). Celastrol improved H9c2 survival under hypoxic stress, and functional analysis revealed HSF1 and HO‐1 as key effectors of the HSR, induced by celastrol, in promoting cytoprotection. In the rat ischaemic myocardium, celastrol treatment improved cardiac function and reduced adverse left ventricular remodelling at 14 days. Celastrol triggered expression of cardioprotective HO‐1 and inhibited fibrosis and infarct size. In the peri‐infarct area, celastrol reduced myofibroblast and macrophage infiltration, while attenuating up‐regulation of TGF‐β and collagen genes.Conclusions and Implications: Celastrol treatment induced an HSR through activation of HSF1 with up‐regulation of HO‐1 as the key effector, promoting cardiomyocyte survival, reduction of injury and adverse remodelling with preservation of cardiac function. Celastrol may represent a novel potent pharmacological cardioprotective agent mimicking ischaemic conditioning that could have a valuable impact in the treatment of myocardial infarction.

1 December 2016 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
NNNicolas Noiseux
Nicolas Noiseux
SMSamer Mansour
Samer Mansour
RWRichard Weisel
Richard Weisel
LSLouis-Mathieu Stevens
Louis-Mathieu Stevens
SSShant Der Sarkissian
Shant Der Sarkissian
TYTerrence M. Yau
Terrence M. Yau

12 November 2009 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
SMSamer Mansour
Samer Mansour
DRDenis-Claude Roy
Denis-Claude Roy
VBVincent Bouchard
Vincent Bouchard
BNBa Khoi Nguyen
Ba Khoi Nguyen
LSLouis Mathieu Stevens
Louis Mathieu Stevens
NNNicolas Noiseux
Nicolas Noiseux